NCT06666426

Brief Summary

This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their quality of life before and after using the device.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
171

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 28, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 30, 2024

Completed
1 day until next milestone

Study Start

First participant enrolled

October 31, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

July 24, 2025

Status Verified

July 1, 2025

Enrollment Period

8 months

First QC Date

October 28, 2024

Last Update Submit

July 22, 2025

Conditions

Keywords

nighttime urinary incontinenceQuality of Lifesleep disturbanceNQoLPROMISPurewickHollisterfemalesPureWick Flex Female External CatheterPureWick Urine Collection SystemThe Hollister Female Urinary PouchBDBecton, Dickinson and Company

Outcome Measures

Primary Outcomes (2)

  • Performance of the PureWick System in the home setting

    Daily capture rate (captured as % of urine captured by device and collected in canister, measured by weight)

    From enrollment to the end of treatment at 4 weeks

  • Safety of the PureWick System in the home setting

    Daily skin irritation score using the 5-point Draize dermal irritation scoring system ranging from 0 to 4 with higher scores indicating greater irritation.

    From enrollment to the end of treatment at 4 weeks

Secondary Outcomes (3)

  • Participant Device Tolerance

    From enrollment to the end of treatment at 4 weeks

  • Participant Device Experience - Comfort

    From enrollment to the end of treatment at 4 weeks

  • Participant Device Experience - Ease of Use

    From enrollment to the end of treatment at 4 weeks

Other Outcomes (2)

  • Nocturnal Incontinence related Quality of Life

    From enrollment to the end of treatment at 4 weeks

  • Participant Sleep Quality

    From enrollment to the end of treatment at 4 weeks

Study Arms (2)

Hollister

ACTIVE COMPARATOR
Device: Hollister Female Urinary Pouch External Collection Device

PureWick

EXPERIMENTAL
Device: PureWick System

Interventions

The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.

PureWick

The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.

Hollister

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult Female Participants greater than or equal to 18 years of age at the time of signing the informed consent.
  • Currently use diapers or equivalent at night for urine output management.
  • Willing to comply with all study procedures in this CIP.
  • Provision of signed and dated informed consent form.

You may not qualify if:

  • Has frequent episodes of bowel incontinence without a fecal management system in place; or
  • Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or
  • Has urinary tract, vaginal or other chronic infections, active genital herpes; or
  • Has urinary retention; or
  • Is agitated, combative, and/or uncooperative and may remove the external catheter or pouch; or
  • Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or
  • Has any pre-existing neurological, psychiatric, or other condition that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator; or
  • Is known to be pregnant at time of enrollment (for women of childbearing age); or
  • Any other condition that, in the opinion of the investigator, would preclude them from participating in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Lakeview Clinical Research

Guntersville, Alabama, 35976, United States

Location

New Horizons Clinical Trials

Chandler, Arizona, 85224, United States

Location

The Practice of Medicine INC.

Eagle Rock, California, 90041, United States

Location

Finlay Medical Research

Greenacres City, Florida, 33467, United States

Location

Finlay Medical Research

Miami, Florida, 33126, United States

Location

Smith Medical Center

Dunwoody, Georgia, 30338, United States

Location

Sonar Clinical Research

Riverdale, Georgia, 30274, United States

Location

Leavitt Clinical Research

Idaho Falls, Idaho, 83404, United States

Location

Research Integrity

Owensboro, Kentucky, 42303, United States

Location

Revive Research Institute

Dearborn Heights, Michigan, 48127, United States

Location

Trialfinity Clinical Research Center

Hamilton, New Jersey, 08619, United States

Location

Albuquerque Clinical Trials

Albuquerque, New Mexico, 87102, United States

Location

Prime Global Research

The Bronx, New York, 10456, United States

Location

MultiSpecialty Clinical Research

Johnson City, Tennessee, 37604, United States

Location

Trio Clinical Trials

Houston, Texas, 77008, United States

Location

Related Publications (1)

  • Medina JC, Fakih M, Khalsa S, Redmond D, Kennelly MJ. Safety, Efficacy, and Patient-Reported Outcomes of the PureWick System Versus Comparator for Nocturnal Urinary Incontinence in the Home Setting: Results of a Randomized Trial. J Clin Med. 2025 Dec 9;14(24):8699. doi: 10.3390/jcm14248699.

MeSH Terms

Conditions

Nocturnal EnuresisUrinary IncontinenceParasomnias

Condition Hierarchy (Ancestors)

EnuresisUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesBehavioral SymptomsBehaviorElimination DisordersMental DisordersLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSleep Wake DisordersNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 28, 2024

First Posted

October 30, 2024

Study Start

October 31, 2024

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

July 24, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations